NEW YORK, Sept. 2, 2010 (GLOBE NEWSWIRE) -- Regenicin, Inc. (OTCBB:WDSTD), a clinical-stage biotechnology company, announced today that it will hold a media and investor conference at the NASDAQ MarketSite on Tuesday, September 14, 2010 at 1pm EDT. CEO Randy McCoy, senior executives and board members will be present.
This conference follows on Regenicin's recent announcement of the appoint of Amgen Co-founder Dr. Joseph Rubinfeld to their Board of Directors.
When: September 14, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY (43th and Broadway)
RSVP required for building security: Call 212.691.8000 or email strell@sunshinesachs.com
Mr. McCoy and his team will be available for interviews prior and post conference. Please contact Jay Strell, strell@sunshinesachs.com or 212.691.8000.
About Regenicin
Regenicin, Inc. is a development-stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. It is devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets with PermaDerm, which is the only tissue-engineered skin prepared from a patient's own skin cells. The company is headquartered in New York, NY.
